Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P05231 (
interleukin-6
)
23,907
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
In this study, we tested if
interleukin-6
(
IL-6
) plays a role in mediating the effects of oxidized phospholipids (OXPL). Treatment of HepG2 cells with oxidized 1-palmitoyl-2-arachidonyl-sn-glycero-3-phosphoryl choline (OX-PAPC), or biologically active lipids present in mildly oxidized low density lipoprotein, increased apolipoprotein J (apoJ), and decreased paraoxonase (PON) mRNA levels. Antibodies to
IL-6
blocked these changes.
IL-6
treatment in the absence of OXPL produced the same pattern of mRNA changes observed with OXPL treatment alone. In vivo, OX-
PAPC
injected into C57BL/6J mice resulted in a marked reduction in PON activity and an increase in apoJ levels in plasma after 16 h. Injection of OX-
PAPC
into
IL-6
-deficient C57BL/6J mice (
IL-6
-/-) did not alter either PON activity or apoJ levels. We then tested if other mechanisms involved in fatty streak formation depended upon
IL-6
. Antibody to
IL-6
had no effect on OX-
PAPC
-induced secretion of MCP-1 by endothelial cells nor on MCP-1 mRNA expression in HepG2 cells. C57BL/6J and
IL-6
-/- mice fed an atherogenic diet both demonstrated markedly reduced plasma PON activities and the
IL-6
-/- mice developed fatty streaks to a greater degree than wild-type mice. We conclude that
IL-6
is critical to short term but not long term regulation of PON and that
IL-6
is not required for OXPL regulation of MCP-1.
...
PMID:Oxidized phospholipids induce changes in hepatic paraoxonase and ApoJ but not monocyte chemoattractant protein-1 via interleukin-6. 1103 96
Epidemiological evidence suggests that cardiovascular disease is associated with osteoporosis, independent of age. Bone resorptive surface is increased in mice on a high-fat diet, and osteoclastic differentiation of bone marrow preosteoclasts is promoted by oxidized phospholipids. Because osteoclastic differentiation requires cytokines produced by osteoblasts, we hypothesized that the stimulatory mechanism of oxidized phospholipids is via induction of osteoclast-regulating cytokines in osteoblasts. To investigate the effects of oxidized phospholipids on expression of such cytokines, murine calvarial preosteoblasts, MC3T3-E1, were treated with oxidized 1-palmitoyl-2-arachidonyl-sn-glycero-3-phosphocholine (ox-PAPC), an active component of oxidized lipoproteins. Results showed that ox-
PAPC
increased expression of
interleukin-6
(
IL-6
) and tumor necrosis factor-alpha.
IL-6
expression was also elevated in calvarial tissues from hyperlipidemic but not in wild-type mice. Ox-
PAPC
also induced
IL-6
protein levels in both MC3T3-E1 and primary calvarial cells. Promoter-reporter assay analysis showed that ox-
PAPC
, but not
PAPC
, induced murine
IL-6
promoter activity. Effects of ox-
PAPC
on
IL-6
expression and the promoter activity were attenuated by H89, a PKA inhibitor. Analysis of deletion and mutant
IL-6
promoter constructs suggested that CAAT/enhancer binding protein (C/EBP) partly mediates the ox-
PAPC
effects. Taken together, the data suggest that oxidized phospholipids induce
IL-6
expression in osteoblasts in part via C/EBP.
...
PMID:Regulation of interleukin-6 expression in osteoblasts by oxidized phospholipids. 1996 98